- Home
- PRLD vs RPTX Comparison
PRLD vs RPTX Comparison
Compare PRLD & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- RPTX
- Stock Information
- Founded
- PRLD 2016
- RPTX 2016
- Country
- PRLD United States
- RPTX Canada
- Employees
- PRLD N/A
- RPTX N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- RPTX Health Care
- Exchange
- PRLD Nasdaq
- RPTX Nasdaq
- Market Cap
- PRLD 69.1M
- RPTX 78.2M
- IPO Year
- PRLD 2020
- RPTX 2020
- Fundamental
- Price
- PRLD $1.36
- RPTX $1.72
- Analyst Decision
- PRLD Strong Buy
- RPTX Strong Buy
- Analyst Count
- PRLD 3
- RPTX 3
- Target Price
- PRLD $4.00
- RPTX $3.50
- AVG Volume (30 Days)
- PRLD 3.2M
- RPTX 197.6K
- Earning Date
- PRLD 10-31-2025
- RPTX 11-07-2025
- Dividend Yield
- PRLD N/A
- RPTX N/A
- EPS Growth
- PRLD N/A
- RPTX N/A
- EPS
- PRLD N/A
- RPTX N/A
- Revenue
- PRLD $7,000,000.00
- RPTX $250,000.00
- Revenue This Year
- PRLD N/A
- RPTX N/A
- Revenue Next Year
- PRLD N/A
- RPTX N/A
- P/E Ratio
- PRLD N/A
- RPTX N/A
- Revenue Growth
- PRLD N/A
- RPTX N/A
- 52 Week Low
- PRLD $0.61
- RPTX $0.89
- 52 Week High
- PRLD $4.22
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- PRLD 47.51
- RPTX 38.26
- Support Level
- PRLD $1.43
- RPTX $1.75
- Resistance Level
- PRLD $4.19
- RPTX $1.87
- Average True Range (ATR)
- PRLD 0.40
- RPTX 0.08
- MACD
- PRLD -0.01
- RPTX -0.02
- Stochastic Oscillator
- PRLD 6.44
- RPTX 11.48
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.